Lantheus Medical Imaging revived plans for an initial public offering last week, but didn’t set any terms for the flotation.
It’s the 2nd run at the public markets for Billerica, Mass.-based Lantheus, which makes medical imaging isotopes.
Lantheus scuppered its 1st IPO attempt in July, setting a range of $12 to $15 per share, for gross proceeds of $111.1 million to $138.9 million.
At the midpoint of that range, Lantheus would have commanded a fully diluted market capitalization of $370 million.
Lantheus reported a 5.2% sales gain for the 1st half of 2014 and said it slashed losses by nearly 93% compared with the same period last year, posting losses of -$2.6 million on sales of $148.9 for the 6 months ended June 30.
In March, Lantheus exited a federal tax evasion row when it agreed to pay $6.2 million to settle allegations that the company and former parent Bristol-Myers Squibb schemed to avoid paying sales taxes.